What Researchers Did
Researchers conducted an interim safety analysis of a randomized controlled trial to evaluate hyperbaric oxygen therapy (HBOT) for severe COVID-19 in critically ill patients with moderate acute respiratory distress syndrome (ARDS).
What They Found
Among 31 patients, adverse events were common, with hypoxia being the most frequent. There was no statistically significant difference in adverse events between the HBOT and control groups. Numerically, serious adverse events and barotrauma were more frequent in the control group, and differences in the PaO2/FiO2 ratio favored HBOT.
What This Means for Canadian Patients
This interim report suggests that hyperbaric oxygen therapy may be a safe intervention for critically ill Canadian patients with COVID-19-induced moderate-to-severe ARDS. However, further research is needed to confirm its efficacy and widespread applicability in Canadian healthcare settings.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This interim analysis involved a small sample size of 31 patients, limiting the generalizability of the findings.